Immune and metabolic pathways of microbial population structure remodeling in biopharmaceuticals for intestinal diseases
Abstract
Gut microorganisms have become a hot spot of scientific research at home and abroad in recent years, in which the study of correlation between microbial community structure and intestinal diseases can provide theoretical basis for biopharmaceuticals for intestinal diseases. In this paper, we constructed in vitro simulated gastric and small intestinal digestion models, as well as large intestinal microbial fermentation models, to study the relative molecular weight and spatial structure changes of β-glucan in simulated gastric and small intestinal regions, and investigated the degradation of β-glucan in simulated large intestinal regions as well as its effects on intestinal microorganisms. In addition to the biochemical and metabolic aspects, integrating biomechanical principles into this research can enhance our understanding of how gut microbes interact with the host’s physiological environment. For instance, the biomechanical properties of the gut—such as motility, peristalsis, and the mechanical forces exerted on microbial populations—can influence the distribution and activity of gut microorganisms. Understanding these biomechanical factors may reveal how they affect the degradation of β-glucan and the overall microbial community structure. Secondly, fecal microorganisms from different batches of mice and different individuals of human volunteers were collected as inoculum for fermentation of β-glucan, to analyze the main microorganisms that stably responded to β-glucan in different batches of fermentation experiments as well as in gut microorganisms from different individuals and to further investigate the metabolic changes, metabolic pathways as well as the biomarkers of β-glucan in the simulated large intestine. L. murinus Mic06, L. murinus Mic07, L. murinus Mic08, and L. murinus Mic094 were validated to be able to utilize β-glucan and produce a small amount of reducing sugars in all four species of Lactobacillus intestinalis in mice, and there was no significant difference in the ability to utilize them; All nine species of human enterobacteriophages were able to utilize β-glucan and produce reducing sugars, with B. xylanisolvens Bac02 and B. koreensis Bac08 having a significantly greater ability to utilize β-glucan. This study contributes to a deeper understanding of gut disease-associated flora and provides strong support for the use of the gut microbiome for multidisease classification. Additionally, considering biomechanical aspects may lead to novel insights into the interactions between gut microbes and host physiology, enhancing the development of targeted biopharmaceuticals.
References
1. Xu, H., Liu, M., Cao, J., Li, X., Fan, D., Xia, Y., ... & Zhao, H. (2019). The dynamic interplay between the gut microbiota and autoimmune diseases. Journal of immunology research, 2019(1), 7546047.
2. Zhang, J., Zhang, J., & Wang, R. (2018). Gut microbiota modulates drug pharmacokinetics. Drug metabolism reviews, 50(3), 357-368.
3. Zhang, X., Han, Y., Huang, W., Jin, M., & Gao, Z. (2021). The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharmaceutica Sinica B, 11(7), 1789-1812.
4. Lindell, A. E., Zimmermann-Kogadeeva, M., & Patil, K. R. (2022). Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota. Nature Reviews Microbiology, 20(7), 431-443.
5. Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., ... & Weersma, R. K. (2020). Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature communications, 11(1), 362.
6. Weersma, R. K., Zhernakova, A., & Fu, J. (2020). Interaction between drugs and the gut microbiome. Gut, 69(8), 1510-1519.
7. Wang, P. X., Deng, X. R., Zhang, C. H., & Yuan, H. J. (2020). Gut microbiota and metabolic syndrome. Chinese Medical Journal, 133
8. Jackson, M. A., Verdi, S., Maxan, M. E., Shin, C. M., Zierer, J., Bowyer, R. C., ... & Steves, C. J. (2018). Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nature communications, 9(1), 2655.
9. Mousa, S., Sarfraz, M., & Mousa, W. K. (2023). The interplay between gut microbiota and oral medications and its impact on advancing precision medicine. Metabolites, 13(5), 674.
10. Koppel, N., Maini Rekdal, V., & Balskus, E. P. (2017). Chemical transformation of xenobiotics by the human gut microbiota. Science, 356(6344), eaag2770.
11. Wilson, I. D., & Nicholson, J. K. (2017). Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Translational Research, 179, 204-222.
12. Fan, Y., & Pedersen, O. (2021). Gut microbiota in human metabolic health and disease. Nature Reviews Microbiology, 19(1), 55-71.
13. Adak, A., & Khan, M. R. (2019). An insight into gut microbiota and its functionalities. Cellular and Molecular Life Sciences, 76, 473-493.
14. Dey, P. (2019). Gut microbiota in phytopharmacology: A comprehensive overview of concepts, reciprocal interactions, biotransformations and mode of actions. Pharmacological research, 147, 104367.
15. Cheng, L., Qi, C., Zhuang, H., Fu, T., & Zhang, X. (2020). gutMDisorder: a comprehensive database for dysbiosis of the gut microbiota in disorders and interventions. Nucleic acids research, 48(D1), D554-D560.
16. Liu, J., Tan, Y., Cheng, H., Zhang, D., Feng, W., & Peng, C. (2022). Functions of gut microbiota metabolites, current status and future perspectives. Aging and disease, 13(4), 1106.
17. Qiu, P., Ishimoto, T., Fu, L., Zhang, J., Zhang, Z., & Liu, Y. (2022). The gut microbiota in inflammatory bowel disease. Frontiers in cellular and infection microbiology, 12, 733992.
18. Le Bastard, Q., Al‐Ghalith, G. A., Grégoire, M., Chapelet, G., Javaudin, F., Dailly, E., ... & Montassier, E. (2018). Systematic review: human gut dysbiosis induced by non‐antibiotic prescription medications. Alimentary pharmacology & therapeutics, 47(3), 332-345.
19. ÁlvarezMercado Ana I. & PlazaDiaz Julio. (2022). Dietary Polysaccharides as Modulators of the Gut Microbiota Ecosystem: An Update on Their Impact on Health. Nutrients(19),4116-4116.
20. Jina Ha, Jinwoo Kim, Seongok Kim, Kwang Jun Lee & Hakdong Shin. (2024). Garlic-Induced Enhancement of Bifidobacterium: Enterotype-Specific Modulation of Gut Microbiota and Probiotic Populations. Microorganisms(10),1971-1971.
21. Dahiya Divakar & Nigam Poonam Singh. (2023). Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota—Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics. International Journal of Molecular Sciences(4),3074-3074.
Copyright (c) 2025 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright on all articles published in this journal is retained by the author(s), while the author(s) grant the publisher as the original publisher to publish the article.
Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International, which means they can be shared, adapted and distributed provided that the original published version is cited.
Submit a Paper
